BLCM Bellicum Pharmaceuticals, Inc. Stock Quote

BLCM [NASD]

Index	-	P/E	-	EPS (ttm)	-0.18	Insider Own	1.50%	Shs Outstand	30.82M	Perf Week	-12.58%
Market Cap	12.34M	Forward P/E	-	EPS next Y	-1.48	Insider Trans	0.00%	Shs Float	8.46M	Perf Month	-20.29%
Income	-6.00M	PEG	-	EPS next Q	-0.69	Inst Own	31.00%	Short Float	2.11%	Perf Quarter	-17.88%
Sales	6.20M	P/S	1.99	EPS this Y	37.10%	Inst Trans	10.44%	Short Ratio	6.31	Perf Half Y	-20.76%
Book/sh	0.57	P/B	2.38	EPS next Y	29.10%	ROA	-17.30%	Target Price	5.00	Perf Year	-54.22%
Cash/sh	4.37	P/C	0.31	EPS next 5Y	-	ROE	-155.70%	52W Range	1.34 - 4.04	Perf YTD	-9.06%
Dividend	-	P/FCF	-	EPS past 5Y	49.50%	ROI	-101.90%	52W High	-66.46%	Beta	1.39
Dividend %	-	Quick Ratio	5.40	Sales past 5Y	74.10%	Gross Margin	-	52W Low	1.12%	ATR	0.14
Employees	7	Current Ratio	5.40	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	38.67	Volatility	10.76% 8.71%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	78.10%	Profit Margin	-96.80%	Rel Volume	1.11	Prev Close	1.42
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	28.26K	Price	1.36
Recom	1.00	SMA20	-9.89%	SMA50	-23.36%	SMA200	-32.96%	Volume	31,293	Change	-4.58%

Oct-30-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$4.50

Oct-30-20

Downgrade

Ladenburg Thalmann

Buy → Neutral

Apr-12-18

Upgrade

Wells Fargo

Market Perform → Outperform

Apr-12-18

Reiterated

Cantor Fitzgerald

Overweight

$10 → $18

Jan-31-18

Reiterated

Cantor Fitzgerald

Overweight

$12 → $10

Jan-31-18

Downgrade

Wells Fargo

Outperform → Market Perform

Mar-08-17

Initiated

Wells Fargo

Outperform

Dec-01-16

Initiated

Raymond James

Outperform

Nov-30-16

Initiated

Ladenburg Thalmann

Buy

Nov-02-16

Initiated

Cantor Fitzgerald

Buy

$32

Aug-09-16

Upgrade

Citigroup

Neutral → Buy

Feb-25-16

Initiated

Citigroup

Neutral

$11

Sep-11-15

Upgrade

Guggenheim

Neutral → Buy

Jul-24-15

Initiated

Citigroup

Buy

May-12-22 04:05PM	Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update GlobeNewswire
May-02-22 07:30AM	Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.13%
Mar-24-22 04:05PM	Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update GlobeNewswire
Jan-26-22 04:05PM	Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference GlobeNewswire
Dec-13-21 04:05PM	Bellicum Regains Compliance with Nasdaq Continued Listing Requirements GlobeNewswire
Dec-10-21 10:26AM	Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021 PR Newswire
Dec-06-21 07:30AM	Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market GlobeNewswire -5.33%
Nov-04-21 04:05PM	Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update GlobeNewswire
Sep-03-21 07:30AM	Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire -7.49%
Sep-01-21 12:00PM	38 Stocks Moving In Wednesday's Mid-Day Session Benzinga +16.83%
07:30AM	Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch GlobeNewswire
Aug-12-21 04:05PM	Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update GlobeNewswire
Jul-26-21 05:25PM	Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-28-21 07:30AM	Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch GlobeNewswire +8.93%
Jun-13-21 02:11PM	Should I Avoid Bellicum Pharmaceuticals Inc (BLCM)? Insider Monkey
May-17-21 07:30AM	Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update GlobeNewswire
Mar-30-21 04:05PM	Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update GlobeNewswire -6.37%
02:45PM	Bellicum Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:06AM	The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga
Mar-23-21 04:05PM	Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update GlobeNewswire -9.68%
Mar-04-21 08:39AM	Bellicum Shares Are Trading Higher On First Reported Positive Clinical Use Of iC9 Safety Switch Benzinga
07:30AM	Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity GlobeNewswire
Feb-08-21 08:30AM	Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin PR Newswire +6.01%
Jan-28-21 04:05PM	Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial GlobeNewswire
Jan-07-21 08:19AM	Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech Zacks
Jan-06-21 08:43AM	Bet on Rising P/E With These 5 Top-Ranked Stocks Zacks
Dec-25-20 12:00PM	Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why Zacks
Dec-18-20 07:39AM	Bet on Rising P/E Investing With These Top 5 Stocks Zacks
Dec-10-20 07:30AM	Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603 GlobeNewswire
Dec-07-20 07:47AM	FDA places clinical hold on Bellicum's cancer therapy Reuters -9.71%
07:30AM	Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial GlobeNewswire
Nov-27-20 04:12PM	Is Bellicum Pharmaceuticals Inc (BLCM) A Good Stock To Buy? Insider Monkey
Nov-25-20 10:31AM	Cronos Group (CRON) Catches Eye: Stock Jumps 9.3% Zacks +6.14%
Nov-20-20 12:00PM	Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's What You Should Know Zacks +5.56%
Nov-19-20 07:41AM	Rising P/E: An Ignored Trick to Pick 5 Winning Stocks Zacks
Nov-05-20 04:05PM	Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update GlobeNewswire
Nov-03-20 08:26PM	Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering GlobeNewswire
Oct-30-20 01:03PM	Bellicum Pharmaceuticals to cut 79% of staff after disappointing trial data, stock suffering record plunge MarketWatch -37.12%
Oct-29-20 05:16PM	Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market GlobeNewswire -7.81%
05:15PM	Bellicum Announces Interim BPX-601 Data and Corporate Restructuring GlobeNewswire
Sep-30-20 04:07PM	Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-28-20 07:30AM	Bellicum to Participate in Two Upcoming Virtual Conferences GlobeNewswire
Sep-18-20 11:31AM	Wells Fargo: These 2 Stocks Could Deliver Triple-Digit Wins TipRanks +12.17%
Sep-02-20 07:30AM	Bellicum to Participate in Two Upcoming Virtual Investor Conferences GlobeNewswire
Aug-31-20 04:07PM	Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-06-20 04:05PM	Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update GlobeNewswire
Jul-31-20 04:08PM	Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-30-20 04:05PM	Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
Jun-15-20 07:30AM	Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors GlobeNewswire +9.35%
Jun-12-20 10:44AM	Here is What Hedge Funds Think About Bellicum Pharmaceuticals Inc (BLCM) Insider Monkey +6.94%
Jun-03-20 09:00AM	47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th ACCESSWIRE
Jun-01-20 10:45AM	Top Ranked Momentum Stocks to Buy for June 1st Zacks +14.29%
May-29-20 04:06PM	Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +9.63%
May-27-20 04:05PM	Bellicum Announces Publication of Data for GoCAR-NK Cell Program GlobeNewswire
07:30AM	Bellicum to Participate in Two Upcoming Virtual Investor Conferences GlobeNewswire
May-22-20 12:00PM	All You Need to Know About Bellicum Pharmaceuticals (BLCM) Rating Upgrade to Strong Buy Zacks +13.22%
May-07-20 04:05PM	Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update GlobeNewswire +8.56%
May-06-20 10:29AM	The Bellicum Pharmaceuticals (NASDAQ:BLCM) Share Price Is Down 98% So Some Shareholders Are Very Salty Simply Wall St. +5.11%
Apr-30-20 04:09PM	Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -8.74%
Apr-17-20 02:44PM	Houston pharma co. completes $15M facility sale to M.D. Anderson as drug research stalls American City Business Journals
Apr-15-20 07:30AM	Bellicum Completes Sale of Houston Facility GlobeNewswire
Mar-31-20 10:55AM	Edited Transcript of BLCM earnings conference call or presentation 12-Mar-20 9:00pm GMT Thomson Reuters StreetEvents +7.53%
Mar-12-20 04:05PM	Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update GlobeNewswire -18.93%
03:00PM	Startek, Inc. to Host Earnings Call ACCESSWIRE
03:00PM	Bellicum Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-10-20 06:48AM	Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Insiders Increased Their Holdings Simply Wall St.
Mar-05-20 07:30AM	Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update GlobeNewswire
Mar-03-20 12:30PM	Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-28-20 04:08PM	Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +12.22%
Feb-07-20 09:42AM	Houston biotech firm raises millions; pharma co. enacts reverse stock split American City Business Journals -5.64%
Feb-05-20 12:45PM	Bellicum Announces Reverse Stock Split GlobeNewswire -17.81%
Feb-02-20 07:00AM	Activist Investors Made Moves in Trinity Industries, B. Riley, Axonics Barrons.com
Jan-31-20 04:05PM	Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -8.27%
11:15AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Bellicum Pharmaceuticals, Inc.- BLCM ACCESSWIRE
Jan-25-20 09:25AM	Here's What We Think About Bellicum Pharmaceuticals, Inc.'s (NASDAQ:BLCM) CEO Pay Simply Wall St.
Jan-24-20 07:30AM	Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium GlobeNewswire -12.15%
Jan-22-20 09:33AM	Houston pharma co. to sell facility to MD Anderson Cancer Center American City Business Journals
Jan-21-20 07:30AM	Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson GlobeNewswire -6.11%
Jan-16-20 07:30AM	Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium GlobeNewswire +23.53%
Dec-13-19 02:45PM	Hedge Funds Are Betting On Bellicum Pharmaceuticals Inc (BLCM) Insider Monkey -6.66%
Dec-11-19 07:30AM	Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson GlobeNewswire +40.72%
Dec-10-19 06:42AM	Is Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) A Volatile Stock? Simply Wall St.
Nov-22-19 10:50PM	BELLICUM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Bellicum Pharmaceuticals, Inc. - BLCM Business Wire
Nov-17-19 07:14AM	Edited Transcript of BLCM earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-08-19 07:00AM	Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire +5.46%
Nov-06-19 07:15PM	Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:15PM	Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update GlobeNewswire
Oct-31-19 04:05PM	Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019 GlobeNewswire -7.37%
Oct-30-19 07:30AM	Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire -8.29%
Oct-29-19 10:33AM	Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline Zacks +9.77%
Oct-26-19 08:57AM	Introducing Bellicum Pharmaceuticals (NASDAQ:BLCM), The Stock That Tanked 95% Simply Wall St.
Sep-30-19 04:07PM	Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-23-19 10:54AM	Top Ranked Momentum Stocks to Buy for September 23rd Zacks
Sep-03-19 02:53PM	Do Insiders Own Lots Of Shares In Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)? Simply Wall St.
Aug-30-19 04:08PM	Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-28-19 04:05PM	Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September GlobeNewswire
Aug-21-19 04:05PM	Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement GlobeNewswire
Aug-20-19 03:47PM	Houston pharma co. raises $69.6M through public offering, private placement American City Business Journals
Aug-16-19 10:56AM	CORRECTING and REPLACING -Bellicum Pharmaceuticals, Inc. GlobeNewswire
08:30AM	Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement GlobeNewswire

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huber Reid M	Director	Jan 04	Option Exercise	0.00	19,494	0	19,494	Jan 06 09:51 AM
BROWN JAMES F	Director	Jan 04	Option Exercise	0.00	28,384	0	28,384	Jan 06 09:49 AM
Stonehouse Jon P	Director	Jan 04	Option Exercise	0.00	21,504	0	22,504	Jan 06 09:40 AM
Daly James M	Director	Jan 04	Option Exercise	0.00	14,377	0	14,377	Jan 06 09:39 AM
Klimovsky Judith V	Director	Jan 04	Option Exercise	0.00	14,602	0	14,602	Jan 06 09:34 AM
DAVIS STEPHEN	Director	Jan 04	Option Exercise	0.00	18,715	0	18,715	Jan 06 09:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience